Back to top
more

Vertex Pharmaceuticals (VRTX)

(Delayed Data from NSDQ)

$483.00 USD

483.00
2,259,829

-15.73 (-3.15%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $483.08 +0.08 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Vertex (VRTX) to Report Q4 Earnings: What's in the Cards?

Vertex Pharmaceuticals (VRTX) will report its Q4 results on Jan 31, 2018.

    Vertex (VRTX) Stock Up 70% in a Year's Time: Here's Why

    Vertex Pharmaceuticals' (VRTX) stock rallies on consistent expansion in patient population through label expansions of Kalydeco and Orkambi and positive data readout from pivotal studies.

      Celgene (CELG) Q4 Preview: Will It Beat on Earnings Again?

      Celgene has an excellent track record and we expect the company to keep the momentum in the fourth quarter. Investors will also focus on updates on recent acqusitions.

        What's in the Cards for Novartis (NVS) This Earnings Season?

        Novartis has an excellent track record. We expect investors to focus on the performance of new drugs and revival of Alcon business.

          Amgen Gets FDA Nod to Add ENDEAVOR Data on Kyprolis Label

          Amgen (AMGN) gets an earlier-than-expected approval to include ENDEAVOR study OS data on Kyprolis label.

            Arpita Dutt headshot

            3 Top-Ranked Drug Stocks that are Broker Favorites

            With the pharma and biotech sector performing well in 2017, here is a look at three drug stocks including Vertex (VRTX) that are broker favorites.

              BlackRock, Pier One Imports, Alkermes, Vertex Pharmaceuticals and Agenus highlighted as Zacks Bull and Bear of the Day

              BlackRock, Pier One Imports, Alkermes, Vertex Pharmaceuticals and Agenus highlighted as Zacks Bull and Bear of the Day

                Arpita Dutt headshot

                Biotech Stock Roundup: Juno Surges on Acquisition Rumor, Concert Down on Patent News

                Is Celgene (CELG) in talks with Juno regarding a possible acquisition deal? This was the main news in the biotech sector this week.

                  3 Biotech Stocks Start Healthy in '18: Will the Rally Last?

                  We take a look at some biotech stocks that have witnessed an increase in their share price this year so far and look well positioned for the rest of 2018.

                    Concert Pharmaceuticals Plunges on Patent Petition Setback

                    Shares of Concert Pharmaceuticals (CNCE) nosedive after the Patent Trial and Appeal Board decided not to grant a Post Grant Review petition in patent '335 dispute with Incyte.

                      The Zacks Analyst Blog Highlights: Celgene, Amgen, Exelixis, Alexion and Vertex

                      The Zacks Analyst Blog Highlights: Celgene, Amgen, Exelixis, Alexion and Vertex

                        Can Biotech Keep Last Year's Momentum Alive in 2018?

                        The biotech sector performed impressively in 2017 and the momentum is expected to continue in 2018 driven by new drug approvals. Acquisitions will also remain in focus.

                          Vertex's Cystic Fibrosis Drug Ok'd for Pediatric Use in EU

                          Vertex (VRTX) receives extension of the marketing application for Orkambi to include use in children with CF who have two copies of the F508del mutation from European Commission.

                            Arpita Dutt headshot

                            Biotech Stock Roundup: Celgene to Acquire Impact, J.P. Morgan Healthcare Conference in Focus

                            Focus this week was on preliminary results and 2018 outlooks provided by several companies including Celgene (CELG) at a healthcare conference.

                              Galapagos Reports Topline Data From Osteoarthritis Study

                              Galapagos' (GLPG) osteoarthritis candidate, GLPG1972, reduces level of ARGS neoepitope, a cartilage breakdown biomarker, by more than half in an early stage study.

                                Will These 2 Large-Cap Biotechs Be on Investor Radar in '18?

                                Both Vertex and Alexion enjoy dominant positions in medical areas - cystic fibrosis (CF) for Vertex and ultra-rare disorders for Alexion - that are not very competitive.

                                  Arpita Dutt headshot

                                  Biotech Stock Roundup: BIIB, CELG Hit by Pipeline News, Acquisition Deals for Ignyta, Sucampo

                                  A couple of acquisition agreements as well as pipeline news from Celgene (CELG) and Biogen were the key highlights this week in the biotech sector.

                                    Arpita Dutt headshot

                                    Biotech Stock Roundup: Label Expansion for Exelixis's Cabometyx, FDA Nod for Spark's Gene Therapy

                                    A one-time gene therapy for an inherited retinal disease gained FDA approval this week while Exelixis's (EXEL) Cabometyx can now be used in treatment-naive advanced renal cell carcinoma patients.

                                      Sweta Killa headshot

                                      5 Hot Stocks Driving the Nasdaq ETF Rally

                                      Inside the top performing stocks of the Nasdaq ETF.

                                        Proteostasis Stock Surges on Positive Data From CF Studies

                                        Proteostasis (PTI) stock skyrockets on positive results from early and mid-stage studies on its cystic fibrosis pipeline candidates.

                                          Arpita Dutt headshot

                                          Biotech Stock Roundup: ASH Data in Focus, Gilead to Buy Cell Design Labs

                                          The annual meeting of the American Society of Hematology was the key highlight this week with several companies like bluebird (BLUE) presenting data on their investigational treatments.

                                            Vertex Kalydeco Study Successful in Children Aged 1-2 Years

                                            Vertex Pharmaceuticals' (VRTX) phase III study evaluating Kalydeco in children as young as one year meets its primary safety endpoint.

                                              Sanghamitra Saha headshot

                                              New Pharma ETF PILL : What Investors Need to Know

                                              Inside the pros and cons of the pharma sector and chances of outperformance of the just-launched fund PILL.

                                                The Zacks Analyst Blog Highlights: Starbucks, NIKE, Manulife, Intuit and Vertex

                                                The Zacks Analyst Blog Highlights: Starbucks, NIKE, Manulife, Intuit and Vertex

                                                  Mark Vickery headshot

                                                  Top Analyst Reports for Starbucks, NIKE & Manulife

                                                  Today's Research Daily features new research reports on 16 major stocks, including Starbucks (SBUX), NIKE (NKE) and Manulife (MFC).